MedTrace Logo

Active Surveillance Research Program for the Assessment of the Safety and the Effectiveness of Linagliptin

NCT02197078 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 189426

Last updated 2020-04-02

Study results available
· View outcomes & findings →

Summary

This protocol is for a series of comparative effectiveness and safety analyses within periodically updated cohorts of patients initiating linagliptin, other DPP-4 inhibitors, and other oral hypoglycemic medications, followed longitudinally for the occurrence of a variety of health outcomes. The primary analysis will be conducted among patients without prior within-class medication use.

Conditions

  • Diabetes Mellitus, Type 2

Sponsors & Collaborators

Principal Investigators

  • Boehringer Ingelheim · Boehringer Ingelheim

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-07-30
Primary Completion
2019-02-26
Completion
2019-02-26

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02197078 on ClinicalTrials.gov